Back to top
more

Cullinan Therapeutics, Inc. (CGEM)

(Real Time Quote from BATS)

$7.39 USD

7.39
157,921

-0.49 (-6.22%)

Updated Aug 7, 2025 12:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 292.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.

Zacks Equity Research

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Zacks Equity Research

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

Zacks Equity Research

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

Zacks Equity Research

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Zacks Equity Research

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

by Zacks Equity Research

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

Zacks Equity Research

Celularity (CELU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.

Zacks Equity Research

Company News for Jun 7, 2021

by Zacks Equity Research

Companies in the news are: REGN, CHRS, SENS, CGEM

Zacks Equity Research

Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data

by Zacks Equity Research

Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.